Bridged Bicyclic Carboxylic Acids for Selective RUNX2 Targeting

Solution Overview

Problem

Current treatments for osteosarcoma (OS) and Ewing sarcoma (ES) are highly invasive and have severe side effects, with chemotherapy targeting all rapidly dividing cells and leading to long-term health defects, especially in children, and there are no effective treatments to prevent metastasis or improve survival rates.

Innovation Solution

A composition comprising a compound of formula (I), such as 3-(N-(3,4-dichlorophenyl)carbamoyl)-5-norbornene-2-carboxylic acid (CADD522), which specifically targets the aberrant expression and activity of the RUNX2 protein in OS and ES cells, inhibiting metastasis and providing an alternative to cytotoxic chemotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy is used to treat osteosarcoma and Ewing sarcoma, then tumor cells are targeted and killed, but severe side effects occur including damage to healthy rapidly dividing cells and long-term health defects

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing a compound that specifically targets RUNX2 protein activity in tumor cells rather than affecting all rapidly dividing cells. The compound of formula (I) with specific structural features (bridged cycloalkenyl ring R4 and substituents R1-R3) selectively inhibits RUNX2 in osteosarcoma and Ewing sarcoma cells, sparing healthy tissues from chemotherapy-induced damage while maintaining effective tumor cell killing.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying the chemical structure to create a compound with selective affinity for RUNX2 in cancer cells. The specific parameters including the bridged cycloalkenyl ring structure and substituent patterns are optimized to change the drug's target specificity, allowing it to distinguish between malignant and healthy cells based on RUNX2 expression and activity levels.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If surgery is used to remove tumors, then localized cancer tissue is removed, but invasive procedures and incomplete removal risks occur

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies the extraction principle by removing the need for invasive surgical intervention through pharmacological treatment. The compound of formula (I) extracts the therapeutic function from surgery by providing a chemical means to kill tumor cells systemically, eliminating the need for physically removing tissue through amputation or excision procedures.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces the mechanical surgical system with a chemical pharmacological system. Instead of using surgical instruments to physically remove tumors, the invention uses a small molecule compound that chemically interferes with RUNX2 protein function, substituting mechanical tissue removal with biochemical tumor cell destruction.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If conventional chemotherapy is used, then systemic treatment is provided, but metastasis prevention is ineffective and survival rates remain stagnant

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by targeting RUNX2 protein activity early in the disease process to prevent metastasis before it occurs. The compound of formula (I) interferes with RUNX2-mediated transcriptional activity that drives metastatic progression, acting preemptively to stop cancer spread rather than treating established metastases.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses RUNX2 protein as an intermediary target to achieve systemic anti-tumor and anti-metastatic effects. The compound of formula (I) does not directly kill tumor cells but instead mediates its effect by inhibiting RUNX2 transcription factor activity, which in turn suppresses metastatic gene expression programs and prevents cancer spread throughout the body.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS20250312300A1Bridged bicyclic carboxylic acids for treating osteosarcoma and ewing sarcoma
Publication Date: 2025.10.09
  • US20250312300A1 patent drawing
  • US20250312300A1 patent drawing
  • US20250312300A1 patent drawing

AI summary

The present invention provides a composition for use in a method of treating osteosarcoma, Ewing sarcoma and/or a metastatic cancer originating from osteosarcoma or Ewing sarcoma. The present invention also provides a method of treating a cancer selected from the group consisting of osteosarcoma, Ewing sarcoma, a metastatic cancer originating from an osteosarcoma and a metastatic cancer originating from Ewing sarcoma.